ライフサイエンスコーパス: drug metabolism

1 dy reveals an unexpected function of RIDD in drug metabolism.

2 rgets showed strong enrichment for lipid and drug metabolism.

3 netic memory and a permanent change of liver drug metabolism.

4 responses in these target genes involved in drug metabolism.

5 netic memory and a permanent change of liver drug metabolism.

6 adigm for unraveling bacterial mechanisms in drug metabolism.

7 lls exhibit differences related to lipid and drug metabolism.

8 etabolizing enzymes with a prominent role in drug metabolism.

9 monal regulation and antibiotic synthesis to drug metabolism.

10 f I3S can lead to AHR activation and altered drug metabolism.

11 with altered cardiovascular disease risk and drug metabolism.

12 P450 3A4, one of the key enzymes involved in drug metabolism.

13 ive antiretroviral therapy agents can affect drug metabolism.

14 ymes and transporters involved in xenobiotic/drug metabolism.

15 ifically contribute to diurnal modulation of drug metabolism.

16 pic data sets collected in parallel to study drug metabolism.

17 processes ranging from cellular adhesion to drug metabolism.

18 s a significant P450 protein responsible for drug metabolism.

19 pidly analyze interindividual differences in drug metabolism.

20 R and potentially expands the role of AhR in drug metabolism.

21 The expanded cells displayed typical human drug metabolism.

22 tions, specifically cytochrome P450-mediated drug metabolism.

23 P3A) is an enzyme of paramount importance to drug metabolism.

24 and other tissues for immune modulation and drug metabolism.

25 tion of genes that regulate angiogenesis and drug metabolism.

26 as a trigger for both enzyme expression and drug metabolism.

27 doses of midazolam, and in case of impaired drug metabolism.

28 now warranted to identify putative roles in drug metabolism.

29 d human pregnane X receptor (hPXR) regulates drug metabolism.

30 of hormone response, clinical research, and drug metabolism.

31 e P450 2D6, a major human enzyme involved in drug metabolism.

32 lems in bioanalysis for pharmacokinetics and drug metabolism.

33 and are substrates for the same pathways of drug metabolism.

34 idual differences in extrahepatic microsomal drug metabolism.

35 reasingly well-recognized site of first-pass drug metabolism.

36 are the primary enzymes involved in phase I drug metabolism.

37 roduced endogenously during tissue injury or drug metabolism.

38 development of complex diseases, and impact drug metabolism.

39 investigate CYP3A functions, especially for drug metabolism.

40 ding bile acid, cholesterol, fatty acid, and drug metabolism.

41 raphy-mass spectrometry (LC-MS) for studying drug metabolism.

42 potential to suppress PXR-regulated phase-I drug metabolism.

43 ese findings have important implications for drug metabolism.

44 ng lipid metabolism, cell proliferation, and drug metabolism.

45 ized as a xenobiotic receptor that regulates drug metabolism.

46 administrated methylphenidate increases the drug metabolism activity and the neurotransmitter levels

47 FLD is associated with reduced in vivo CYP3A drug-metabolism activity and hepatic CYP3A4 expression i

48 ediated down-regulation, thereby normalizing drug metabolism after rewarming.

49 is known about the impact of hypothermia on drug metabolism after rewarming.

50 Comparison of EME-MS with LC-MS for drug metabolism analysis demonstrated for the first time

51 The CYP3A4 is involved in drug metabolism and acquisition of drug resistance.

52 Muscle is also important in drug metabolism and adverse events, and the application

53 actions that can lead to altered kinetics in drug metabolism and altered elimination rates in vivo.

54 ormation, such as drug-to-antibody ratio and drug metabolism and are more readily analyzed by electro

55 We discovered that several drug metabolism and BA transporter genes were down-regul

56 cytochrome P450 (CYP) gene family catalyzes drug metabolism and bioactivation and is therefore relev

57 n turnover can influence clinically relevant drug metabolism and bioavailability and drug-drug intera

58 apeutic protocols, and ethnic differences in drug metabolism and bioavailability of the agents common

59 the effects of specific genetic variants on drug metabolism and cancer development.

60 t also in several key areas, particularly in drug metabolism and chemical toxicology, as chemists dea

61 cally relevant inhibitory cross-talk between drug metabolism and cholesterol/glucose metabolism.

62 ne X receptor), a regulator of enterohepatic drug metabolism and clearance, results in an unexpected

63 se, drug-drug interactions, drug dosage, and drug metabolism and clearance.

64 These enzymes dominate drug metabolism and determine drug-drug interactions.

65 coordinated regulation of genes involved in drug metabolism and detoxification as well as maintenanc

66 entrally regulates both phase I and phase II drug metabolism and detoxification.

67 Cytochromes P450 play key roles in drug metabolism and disease by oxidizing a wide variety

68 s of other membrane P450 enzymes involved in drug metabolism and disease states.

69 ted disease screening; crop protection data; drug metabolism and disposition data and bioactivity dat

70 in the expression of other genes involved in drug metabolism and disposition.

71 X receptor (PXR) regulates genes involved in drug metabolism and disposition.

72 cyp2k, cyp3a) and phase II (gstalpha, gstpi) drug metabolism and drug transporters mdr1 and mrp2.

73 o predict the role of human CYP2C enzymes in drug metabolism and drug-drug interactions is limited.

74 The throughput of this platform may enable drug metabolism and drug-drug interactions to be interro

75 ause acute infection and inflammation affect drug metabolism and drug-metabolizing enzymes, the effec

76 ng with ABC transporters that act to control drug metabolism and efflux.

77 ed drugs and serves as a master regulator of drug metabolism and excretion gene expression in mammals

78 yperforin induces the expression of numerous drug metabolism and excretion genes in primary human hep

79 e shown to induce the expression of numerous drug metabolism and excretion proteins.

80 gulates various liver functions ranging from drug metabolism and excretion to energy metabolism.

81 ulator of the expression of genes central to drug metabolism and excretion.

82 Historically, they have a central role in drug metabolism and following the advent of genomics the

83 regulate their target genes, modulating both drug metabolism and gluconeogenesis.

84 chrome P450 enzymes (P450s) are important in drug metabolism and have been linked to adverse drug rea

85 xic oxygen metabolites that are generated by drug metabolism and immune responses in addition to thos

86 tereoselective drug metabolite synthesis and drug metabolism and inhibition assays.

87 new bioanalytical platform of HLM useful for drug metabolism and inhibition assays.

88 ed on additional literature data on in vitro drug metabolism and inhibition potency, loratadine and s

89 The effects of drug metabolism and KCNH2 genotypes on clinical response

90 re oxygenases (cytochromes P450) involved in drug metabolism and many disease states, including liver

91 In vitro and in vivo drug metabolism and pharmacokinetic (DMPK) evaluation al

92 ial dissipation and ROS generation, and good drug metabolism and pharmacokinetic (DMPK) properties fo

93 gents can be modified to possess appropriate drug metabolism and pharmacokinetic properties.

94 s series, and this, alongside early in vitro drug metabolism and pharmacokinetics (DMPK) issues, prec

95 that demonstrated an excellent cross-species drug metabolism and pharmacokinetics (DMPK) profile and

96 This compound demonstrated good preclinical drug metabolism and pharmacokinetics (DMPK) properties a

97 domain inhibitors with excellent potency and drug metabolism and pharmacokinetics (DMPK) properties w

98 r Malaria Venture (MMV) met the efficacy and drug metabolism and pharmacokinetics (DMPK) requirements

99 Sex differences in drug metabolism and pharmacokinetics also occur in human

100 l molecule antagonists with GPR103 affinity, drug metabolism and pharmacokinetics and safety paramete

101 cular chirality remain an important issue in drug metabolism and pharmacokinetics for the pharmaceuti

102 We report in vitro drug metabolism and properties profiling of 4c and show

103 g cooling and the effects after rewarming on drug metabolism and response.

104 gy and pharmacokinetics of 1, along with its drug metabolism and safety assessment.

105 r-deficient PIRF mice can thus predict human drug metabolism and should be useful for preclinical dru

106 IdeS digestion, minimizes assay artifacts of drug metabolism and skewed DAR profiles that may result

107 genetic variants selected a priori based on drug metabolism and targets have the greatest potential

108 athogenesis and focused on genes involved in drug metabolism and the immune response.

109 inal (GI) physiology, GI neuroendocrinology, drug metabolism and toxicity, obesity and liver disease.

110 of liver biology, liver diseases, as well as drug metabolism and toxicity.

111 iocompatibility and relevance for evaluating drug metabolism and toxicity.

112 se modeling, host-pathogen interactions, and drug metabolism and toxicity.

113 ystem will be crucial for studies evaluating drug metabolism and toxicology using in vitro constructs

114 es involved in GC signaling (GR, GLCCI1) and drug metabolism and transport (CYP3A5, ABCB1, and PXR) w

115 id-based therapies from the point of view of drug metabolism and transport to target tissues.

116 It covers all drug metabolism and transportation enzymes.

117 f this isoform is important in understanding drug metabolism and xenobiotic detoxification.

118 of infrared ion spectroscopy in the field of drug metabolism and, more generally, its promising role

119 Expertise in HCV antiviral resistance, drug metabolism, and drug-drug interactions and optimiza

120 P450s play an important role in drug metabolism, and have potential uses as biocatalysts

121 relevance to the evolution of new functions, drug metabolism, and in vitro biocatalyst engineering.

122 s the dominant P450 enzyme involved in human drug metabolism, and its inhibition may result in advers

123 ing decreases cytochrome P450 (CYP)-mediated drug metabolism, and limited clinical data suggest that

124 y acid elongation, cholesterol biosynthesis, drug metabolism, and methemoglobin reduction.

125 ncluding suppression of apoptosis, increased drug metabolism, and modification of target proteins.

126 invaluable for studies of oxidative stress, drug metabolism, and other pathways that involve gamma-g

127 Despite widespread use in pharmacokinetic, drug metabolism, and pesticide residue studies, little i

128 uence GSTP1's contribution to carcinogen and drug metabolism, and possibly disease pathogenesis and/o

129 erial phyla, encoding antibiotic resistance, drug metabolism, and stress response pathways.

130 llosteric pharmacology, medicinal chemistry, drug metabolism, and validated approaches to address eac

131 ndent variations in nitroreductase activity, drug metabolism, and/or actual oxygen gradients.

132 bles, such as drug plasma levels (exposure), drug metabolism, and/or their transport across the blood

133 n in such diverse physiological processes as drug metabolism (approximately 85-90% of therapeutic dru

134 Although the effects of polyI:C on drug metabolism are often attributed to interferon produ

135 P2E1 has in normal physiology, toxicity, and drug metabolism are related to its ability to metabolize

136 Sex-based differences in drug metabolism are the primary cause of sex-dependent p

137 mmune repertory and in genes responsible for drug metabolism, are excellent candidates for the differ

138 mmals experience an aging-related decline in drug metabolism as well as a diminution in growth hormon

139 In humans this may lead to altered drug metabolism, as many of the newly synthesized ligand

140 n on the similarities and dissimilarities in drug metabolism between the young and old, as may be unc

141 ssed cytosolic enzyme important in exogenous drug metabolism but the physiological function of which

142 a transcription factor that induces hepatic drug metabolism by activating cytochrome P450 genes.

143 or drug abuse treatment is to accelerate the drug metabolism by administration of a drug-metabolizing

144 Ub-ligases can influence clinically relevant drug metabolism by effectively regulating the physiologi

145 atories have demonstrated that activation of drug metabolism by P450s may occur via a mechanism that

146 to enable experiments, for example, to study drug metabolism by use of precision-cut liver slices, th

147 coordinated activation of genes involved in drug metabolism, by blocking activation of a specific su

148 terindividual pharmacokinetic differences in drug metabolism can be identified by computational genet

149 Induction of hepatic and intestinal drug metabolism can contribute to the increased metaboli

150 flammatory responses and infections decrease drug metabolism capacity in human and experimental anima

151 he gut microflora has a direct impact on the drug metabolism capacity of the host.

152 ment, individualized subtherapeutic tests of drug metabolism, carbon dating and real time monitoring

153 further delineate the energy metabolism and drug metabolism crosstalk in this study, we exposed HepG

154 his protocol to a key human P450 involved in drug metabolism: CYP3A4.

155 and longevity, notably pathways involved in drug metabolism/degradation (nicotine and melatonin).

156 Hepatic drug metabolism develops early in organogenesis and cont

157 genes are related to disease phenotypes and drug-metabolism differences in the population.

158 bout the importance of nutritional status on drug metabolism, distribution, and effectiveness.

159 sidering in vivo effects such as quiescence, drug metabolism, drug properties, and transport consider

160 uch variations may involve genes controlling drug metabolism, drug transport, disease susceptibility,

161 including synthesis of human proteins, human drug metabolism, drug-drug interaction, and drug-induced

162 echanisms underlying altered CYP2D6-mediated drug metabolism during pregnancy, laying a foundation fo

163 Conventional methods for assaying drug metabolism (e.g., those based on HPLC) have been es

164 carboxylesterase 1 (hCE1), a broad-spectrum drug metabolism enzyme, in covalent acyl-enzyme intermed

165 l structure of any region of a mammalian UGT drug metabolism enzyme.

166 (UGT) are the dominant phase II conjugative drug metabolism enzymes that also play a central role in

167 cription factor regulating the expression of drug metabolism enzymes, including transporters.

168 (hPXR) regulates the expression of critical drug metabolism enzymes.

169 ted for genes involved in small molecule and drug metabolism, especially butyrylcholinesterase (BCHE)

170 ted metabolic and oxidative phosphorylation, drug metabolism, fatty acid metabolism, and intestinal m

171 any pathological conditions, such as altered drug metabolism, fatty liver, and diabetes.

172 nriched for biological processes relevant to drug metabolism for FBZ and FLU, respectively.

173 nderstanding of PXR, the master regulator of drug metabolism gene expression in humans, in its functi

174 istance with higher transcript levels of the drug metabolism gene PTGS1 was confirmed in a separate d

175 ive stress, whereas up-regulation of phase I drug metabolism genes by RXRalpha may render the liver m

176 data suggest that pretreatment evaluation of drug metabolism genes may explain some interindividual d

177 on of hepatic, rather than small intestinal, drug metabolism genes would contribute to the increased

178 DNA was genotyped for 29 polymorphisms in 17 drug metabolism genes.

179 hed for lipid homeostasis, hypertension, and drug metabolism genes.

180 Ralpha to control the expression of numerous drug metabolism genes.

181 ssues, although its relative contribution to drug metabolism has yet to be ascertained.

182 metabolites is a key issue for the study of drug metabolism in biological systems.

183 Untreated type 1 diabetes increases hepatic drug metabolism in both human patients and rodent models

184 serum shock to study how time of day shifts drug metabolism in cells.

185 e in considering interpopulation patterns of drug metabolism in epidemiological and pharmacogenetic s

186 ent in regulating selected genes involved in drug metabolism in fish, but suggest some divergence in

187 ore difficult to treat, due to mechanisms of drug metabolism in hepatic and renal failure, as well as

188 e P450 3A4 (CYP3A4), plays critical roles in drug metabolism in hepatocytes that are either quiescent

189 CYP3A4, the most important P450 catalyst of drug metabolism in human liver.

190 The CAR-dependent induction of drug metabolism in newly diagnosed or poorly managed typ

191 Viral infections are often linked to altered drug metabolism in patients; however, the underlying mol

192 The functional significance of drug metabolism in skin and the implication of CYP in sk

193 ive intermediates generated in the course of drug metabolism in the human liver is of great importanc

194 ally, organ-on-a-chip models demonstrate how drug metabolism in the liver affects multi-organ toxicit

195 well as the implications of liver injury on drug metabolism in this patient population.

196 iologically relevant culture system to study drug metabolism in vitro, were used to investigate this

197 elopment of inhibitors for use in modulating drug metabolism in vivo.

198 arance, a surrogate marker of CYP3A-mediated drug metabolism, in critically ill children.

199 es and in activation of pathways involved in drug metabolism, including those involved in metabolizin

200 amples including human urine sample and P450 drug metabolism incubation mixture were tested.

201 at in vivo administration of polyI:C affects drug metabolism independent of type I interferon product

202 450 enzymes involved in arachidonic acid and drug metabolism, inflammation and immune responses, mito

203 in mouse and rat liver, affecting lipid and drug metabolism, inflammation, and disease.

204 Variation in the CYP3A enzymes, which act in drug metabolism, influences circulating steroid levels a

205 and copper), photosynthesis (manganese) and drug metabolism (iron).

206 GIT microbiota participation in drug metabolism is a further pharmaceutical consideratio

207 Individual variation in drug metabolism is a major cause of unpredictable side e

208 t microbiota directly and indirectly affects drug metabolism is beginning to emerge.

209 contribution of glucuronidation toward human drug metabolism is carried out by the Super gene family

210 Drug metabolism is controlled by a class of orphan nucle

211 During hypothermia, drug metabolism is markedly reduced.

212 P450-catalyzed drug metabolism is obligatorily dependent on electron in

213 mine whether, like other sexual dimorphisms, drug metabolism is permanently imprinted by perinatal ho

214 Although the role of sulfation in drug metabolism is well recognized, an increased underst

215 t area of investigation, the role of PON1 in drug metabolism, is also discussed.

216 CYP) 3A4, the most important enzyme in human drug metabolism, is decreased in uremia.

217 h Quality in Pharmaceutical Development (IQ) Drug Metabolism Leadership Group.

218 the activity of several enzymes involved in drug metabolism, leading to decreased plasma concentrati

219 Examples presented here include drug metabolism, lipid analysis, metabolomics, quantitat

220 ns in electrolyte balance and organ-specific drug metabolism may contribute to complications with the

221 Individual genetic variations in drug metabolism may contribute to increased cardiac even

222 We discuss here the effect of drug metabolism mediated by cytochrome P450 on therapeut

223 Through the extraction of various facts of drug metabolism, not only the DDIs that are explicitly m

224 erent components of the Phase I and Phase II drug metabolism on MMC adduct formation, using either gl

225 o predict pathways of human CYP2D6-dependent drug metabolism on the basis of animal studies.

226 TLs without the involvement of intracellular drug metabolism or antigen processing.

227 tations) or upstream of this interaction, in drug metabolism or drug transport mechanisms.

228 be used to identify variants that influence drug metabolism or interaction of a drug with its cellul

229 nes, such as their doubling time in culture, drug metabolism or the interferon response.

230 prior literature, targeting genes related to drug metabolism, oxidative damage, altered neurotransmis

231 or pharmacodynamics of antileukemic agents, drug metabolism, oxidative stress, and attention problem

232 or measuring the activity of a key enzyme of drug metabolism, P450 3A4.

233 onducted using the search terms hypothermia, drug metabolism, P450, critical care, cardiac arrest, tr

234 n mounting evidence of crosstalk between the drug metabolism pathway and the energy metabolism pathwa

235 PXR plays a vital role in the drug metabolism pathway, and a comprehensive examination

236 Identifying individual genetic variation in drug metabolism pathways is of importance not only in li

237 Testing for variation in other drug metabolism pathways may also become important.

238 m 60 animals with extreme (i.e. fast or slow drug metabolism) pharmacokinetic (PK) profiles were gene

239 important enzyme, improving the outcomes for drug metabolism predictions, and developing pharmaceutic

240 vel high-throughput 96-well plate format for drug metabolism profiling.

241 equirement, surgical site infection, delayed drug metabolism, prolonged recovery, shivering, and ther

242 pe, and with appropriate pharmacokinetic and drug metabolism properties, these compounds could be dev

243 d cell proliferation and survival as well as drug metabolism, providing insights into the pathogenesi

244 The impact of the drug metabolism rate on patient survival was also discus

245 e is known about the role of this pathway in drug metabolism regulation in human liver.

246 Furthermore, alterations in drug targets, drug metabolism, repair of DNA damage caused by drugs, a

247 ces, predictive tools and visualizations for drug metabolism researchers.

248 mate and inextricable role in all aspects of drug metabolism, safety, and effectiveness.

249 important in making accurate predictions of drug metabolism selectivity of P450s using QM/MM methods

250 Genetic and developmental studies on hepatic drug metabolism show that immaturity, polymorphisms, and

251 ulation pharmacology studies, and indeed for drug metabolism studies in general.

252 hip as a complementary tool for a variety of drug metabolism studies in the early stages of drug disc

253 ransplantation, and cytochrome P450 (CYP450) drug metabolism studies), mitigates risk associated with

254 hat it is important to include MAO assays in drug metabolism studies.

255 measurement for metabolite identification in drug metabolism studies.

256 tive to using radioisotopes for carrying out drug metabolism studies.

257 Since glucuronidation is a common pathway of drug metabolism, studies of the frequency with which glu

258 A drug metabolism study revealed that an imidazole, but no

259 acil and flutamide, and is extendable to any drug metabolism study where there is a spin-active X-nuc

260 ) are the major enzymatic detoxification and drug metabolism system.

261 ide hydrolase (sEH) is an enzyme involved in drug metabolism that catalyzes the hydrolysis of epoxide

262 rated within the nucleus, and the 80% of the drug metabolism that occurs in the cytoplasm is probably

263 Optimization of properties related to drug metabolism then culminated in the identification of

264 ses, and the roles for UGT1A1 and SLCO1B1 in drug metabolism, these genetic findings have potential c

265 2C, and CYP2D, which are critical enzymes in drug metabolism, thus affecting the effectiveness of the

266 ish key physiological processes ranging from drug metabolism to steroidogenesis, human microsomal cyt

267 re recognizing differences in tumor biology, drug metabolism, toxicity, and therapeutic response amon

268 ochrome P450s (P450s) play critical roles in drug metabolism, toxicology, and metabolic processes.

269 However, altered drug metabolism, transport, or other related mechanisms

270 nces were observed for GC signaling or other drug metabolism/transport-related genes.

271 CYP2C6 and CYP2C7, both in vitro and in vivo drug metabolism was more rapid in the phenobarbital-impr

272 th IP-related diarrhea; UGT1A1 (G-3156A)A/A (drug metabolism) was associated with IP-related neutrope

273 t of the consequences of differential CYP2D6 drug metabolism, we have developed a novel straightforwa

274 To understand these differences in drug metabolism, we wanted to generate mutations at indi

275 Previous suggestions of autoinduction of drug metabolism were not confirmed by this study.

276 Conversely, genes involved in xenobiotic and drug metabolism were up-regulated, which was linked to i

277 ly widespread in biology and particularly in drug metabolism, where the need for rapid screening of n

278 yed increased cellular growth, movement, and drug metabolism, whereas the center of the lesion was ch

279 efine gene variations responsible for varied drug metabolism, which influences drug efficacy.